FRESH-PEF60115-en
Asthma and Airway Obstruction Cohort: Clinicobiological Cohort Follow-up
COBRA
| Name | Country code |
|---|---|
| France | fr |
['Clinical data','Paraclinical data (non-biological)','Paraclinical data (non-biological) : Imaging','Biological data','Participant-reported health data']
Individuals
| Topic | Vocabulary |
|---|---|
| Pulmonary medicine | health theme |
| Environmental determinants: Climate | health determinant |
| Environmental determinants | health determinant |
{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"Two cohorts: one with asthmatics and one with individuals affected by COBP; subjects included between the ages of 18 and 80 years old. Asthma cohort: including patients who are non-smokers and smokers with compatible clinical history and individuals with a reversible obstructive airway disease, based on a FEV1/CV <75% and an FEV1 baseline value improvement of 12% or 200 ml after inhalation of 400 µg of Salbutamol. COBP cohort: including patients who are smokers (>10 packets per year) presenting with an obstructive airway disease (FEV1/CV <75%) and an FEV1 improvement of less than 10% after inhalation of 200 µg of Salbutamol.","clusion_E":""}
| Name |
|---|
| Michel;AUBIER |
| Name | Role |
|---|---|
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) | sponsor |
| Name |
|---|
| ASTRAZENECA (FRANCE) |
| CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES (CHU) |
| CHIESI (FRANCE) |
| GLAXOSMITHKLINE (FRANCE) |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) |
| Agency name |
|---|
| CNIL |
['Through organizations (health services or institutions, schools, businesses, etc.)']
['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']
Access on specific project only
Observational Study
| Start | End |
|---|---|
| 2008-01-01 | 2018-01-01 |
Contractual access subject to COBRA Scientific Council validation. Research projects that can use clinical and/or biological cohort data are encouraged and validated by the Scientific Council (2 members per centre).
{"value":"Restricted access","extLink":[{"title":"COAR","uri":"http://purl.org/coar/access_right/c_16ec"}]}
Data may be used by academic teams. Data may not be used by industrial teams.
| Name | |
|---|---|
| Michel;AUBIER | michel.aubier@wanadoo.fr |